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ABSTRACT 
The desmosomal cadherin Desmoglein-3 (Dsg3) is a core adhesion component in desmosome junctions 
that occur with high frequency in the stratified squamous epithelial membrane lining the skin and 
mucous membrane. Dsg3 is identified as a major target of the circulating autoantibodies in Pemphigus 
Vulgaris (PV), an autoimmune blistering skin disease, and many signaling pathways have been 
demonstrated to be activated by PV-IgG targeting Dsg3, highlighting its role as a surface regulator in 
cell signaling. A recent study has revealed an unprecedented role of Dsg3 in the suppression of p53 and 
shows dysfunction of this pathway in PV. Furthermore, reciprocal crosstalk between p53 and yes-
associated protein (YAP) downstream of Dsg3 has been observed in keratinocytes in which increased 
YAP expression causes suppression of p53 or vice versa. Both p53 and YAP are the crucial nuclear 
transcription factors involved in regulating cell fate decision, adaptation and tissue integrity in response 
to environmental and biological cues and are mutually exclusive in human cancer. In this review, we 
discuss Dsg3 signaling role in keratinocyte response to stress signals, with the highlight on our recent 
findings of the Dsg3/p53 pathway in the control of cell proliferation and tissue homeostasis, including 
the DNA integrity, beyond its function in cell-cell adhesion.   
Keywords: desmoglein-3, p53, YAP, cell signaling, DNA damage, pemphigus.     
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1. Introduction 
Desmoglein-3 (Dsg3) belongs to a subfamily of the desmosomal cadherins and is an essential 
component of the junctional protein complex known as the desmosome that mediates calcium-
dependent cell-cell adhesion in vertebrate epithelial cells [1]. Desmosomes occur in abundance in 
tissues, such as the skin and mucous membrane that are subjected to extensive mechanical stress. In 
addition to its role in cell-cell adhesion, Dsg3 also functions as a surface regulator for various 
intracellular signaling pathways in epithelial cells [1-7]. Many of these findings are achieved from the 
studies of the pathogenesis of Pemphigus Vulgaris (PV), an autoimmune bullous disease in which Dsg3 
serves as a major autoantigen and is targeted by circulating autoantibodies that cause disruption of 
desmosomes, resulting in blistering affecting both the skin and mucous membrane [2,3,6]. This mini-
review will focus on our recent findings suggesting an unprecedented signaling role of Dsg3 in 
regulating two fundamental pathways that control cell proliferation and cell fate decision [8,9]. The 
involvement of this pathway in the pathogenesis of PV is also discussed briefly in this review.   
 
2. Dsg3 exerts function as a cell signaling regulator  
Several studies have implicated a key role for Dsg3 in mediating outside-in signaling (e.g. Src, 
p38MAPK, PKC, ERK, EGFR, plakoglobin, c-Myc, and Rho GTPases, etc.) involved in desmosome 
remodeling, cell proliferation, differentiation, migration or apoptosis, and thus validating that Dsg3 acts 
as a signaling molecule that has a major impact on tissue integrity and homeostasis [1]. Early studies 
have shown activation of phospholipase C signaling pathway following the binding of PV-IgG to Dsg3 
that leads to disruption of cell cohesion and blister formation [10]. Dysregulation of Dsg3 in the 
suprabasal layers of the skin in the transgenic mouse resulted in increased keratinocyte proliferation 
and altered terminal differentiation suggesting that this basal cell isoform of Dsg is involved in the 
regulation of cell proliferation [11]. Consistent with this finding, another study utilizing Dsg3 depletion 
in HaCaT keratinocytes demonstrated the suppression of cell proliferation and colony growth [12]. Such 
an effect of altered Dsg3 expression on cell proliferation may indicate a link between Dsg3 loss and 
cell cycle control [13]. Owing to the widespread expression of Dsg3 at the plasma membrane, it is 
thought that the non-junctional pool of Dsg3 may be responsible for cell signaling and is the target of 
PV-IgG [14,15]. Tsang et al. have demonstrated that non-junctional Dsg3 acts as an upstream regulator 
of Src via interaction with classical E-cadherin and helps to regulate the formation of adherens junctions 
[15-17]. Overexpression of Dsg3 in epidermoid carcinoma A431 cell line elicits activation of Ezrin and 
AP-1 that are associated with tumor cell migration and invasion [18]. Dsg3 is also found to act as an 
upstream regulator of small Rho GTPases and overexpression of Dsg3 results in increased activity of 
Rac1 and Cdc42 in epithelial cells [17]. In line with this finding, pemphigus IgG binding to Dsg3, as 
well as Desmoglein-1 (Dsg1), interferes with RhoA activity and signaling that is coupled with a range 
of PV-IgG triggered effects, including keratin retraction and release of Dsg3 from the cytoskeleton-
associated protein pool [19,20]. Activation of all these signaling pathways can have an influence on E-
cadherin trafficking and the modulation of E-cadherin mediated junction stability [21]. Besides, 
numerous intracellular signalling events are found to be activated by IgG binding to Dsg3 [2,3,5,6], 
among which is the key pathway p38MAPK. Enhanced phosphorylation of p38MAPK and its 
downstream target HSP27 was detected in keratinocytes treated with PV-IgG and the pathogenic anti-
Dsg3 antibody AK23 [22,23]. Pathways such as PKC, EGFR, Src and c-Myc, among many others, have 
also been implicated in PV pathological signaling events [3,4,23,24]. Inhibition of these pathways can 
alleviate blistering in vitro and in vivo [5,25-27]. Together, these data suggest that Dsg3 is an important 
signaling molecule in human keratinocytes. 
 
3. Dsg3 regulates the p53 pathway  
The Dsg3 bearing tissues such as skin and oral mucosa are constantly exposed to a multitude of stresses 
due to external and internal influences that can potentially lead to genome damage and cellular oxidative 
stress [28-30]. p53 is a central hub in response to all these stress signals via coordinating many cellular 
stress responses to maintain genomic integrity and hence is called a ‘cellular gatekeeper’ [31] and the 
‘guardian of the genome’ [32]. Several studies have highlighted the connection between altered cellular 
3 
 
 
stress response and human diseases, including diabetes and cancer [33]. Ultraviolet (UV) irradiation 
can induce the generation of reactive oxidative species (ROS) [34]. Oxidative stress is shown to be 
involved in numerous skin diseases including psoriasis, lichen planus and pemphigus [35-38]. 
Moreover, p53 overexpression is reported in skin conditions such as psoriasis [39], discoid lupus 
erythematosus (DLE) [40], and pemphigus in two studies with a focus on apoptosis [41,42]. 
Nonetheless, to our best knowledge, no study to date has explored the direct functional association 
between Dsg3 and the p53 pathway except for our recent report [8].  
 
Taking into account that 1) Dsg3 acts as a cell signal regulator for various pathways, 2) our recent study 
shows that Dsg3 exerts a function as a sensor to mechanical stress in keratinocytes [9], and 3) the Dsg3 
bearing tissues are prone to various chemical and physical stresses daily that could induce the p53 
activation [43], we performed a study with a focus on the establishment of the Dsg3/p53 pathway using 
various in vitro and in vivo study approaches, including Dsg3 knockdown and knockout mouse model 
and analysis of PV patient specimens as well as keratinocyte cultures treated with PV-IgG and the 
specific anti-Dsg3 antibody [8]. This study sheds new light on Dsg3’s ability as an anti-stress protein 
by restricting p53 response to stress signals in keratinocytes. The study demonstrated moderate, but 
significant elevated p53 expression in cells harboring wild type p53, with Dsg3 depletion mediated by 
ribonucleic acid interference (RNAi) and this was accompanied by an increased expression of 
p21Waf1/Cip1 and Bax suggesting activation of the p53 pathway (Figure 1). The correlation of increased 
p21Waf1/Cip1 with p53 activation in Dsg3 depleted cells was further elaborated by knocking down of p53 
that resulted in p21Waf1/Cip1 abrogation. The p53 response to stress involves the coordination of cell cycle 
arrest and apoptosis [43] and p53 accomplishes these effects by regulating several genes, primarily 
including p21Waf1/Cip1 and Bax. p21Waf1/Cip1 is upregulated by p53 following DNA damage [44-46] and is 
thought to be an integral part of the p53-mediated growth-arrest pathway [45]. Besides, Bax is a p53 
primary response gene involved in a p53 regulated apoptotic activity by both transcription-dependent 
and independent pathways [47,48]. Thus, the combined upregulation of p53 along with p21Waf1/Cip1 and 
Bax indicates activation of the p53 pathway. These in vitro findings were supported by in vivo study in 
Dsg3 null mice that showed increased expression of p53/p21Waf1/Cip1/cleaved caspase-3 in Dsg3−/− hair 
follicles in dorsal skin samples, but not in Dsg3+/− littermates [8]. Notably, we showed that the 
Dsg3/p53 pathway is Dsg3 specific as neither E-cadherin nor desmoplakin knockdown elicits the same 
effect. Furthermore, this pathway only applies to wild type p53 since modulation of Dsg3 expression in 
A431 cell line that bears p53 mutation failed to induce any changes in p53 with no detection of 
p21Waf1/Cip1. Collectively, these findings are consistent with the hypothesis that Dsg3 plays a role in 
dampening the p53 response to stress that may be required to control the balance of the p53 pathway in 
epithelial cells, in particular in stress-baring tissues.  
 
The stabilization of p53 is a common response to cellular stress and is one of the key mechanisms by 
which the p53 function is regulated. Many tumors that retain wild type p53 show defects in this pathway 
[49]. The stabilization of p53 also seems to be the case in Dsg3 depleted cells since Dsg3 knockdown 
resulted in an increase of the half-life of p53 protein turnover by approximately two-fold. We showed 
that such delayed p53 turnover was accompanied by stabilization of MDM2 that may reflect a negative 
feedback mechanism to control the p53 expression levels [50]. It is worth noting that the stress response 
of p53 can be obscured by the nature of its fast turnover as we demonstrated by treating cells with the 
proteasome inhibitor MG132 that revealed greater differences in the levels of p53 expression between 
the Dsg3 knockdown and control cells [8]. Consistent with the findings from the loss-of-function study, 
overexpression of Dsg3 resulted in an inverse effect with marked suppression of p53 at both protein 
and mRNA levels as well as the p53 transcription activity [8]. Furthermore, this regulatory pathway of 
Dsg3/p53 was consolidated by experiments with several cellular stress responses, such as UV 
irradiation, genotoxic drug treatment and cyclic mechanical strain, which provoked further 
enhancement in the levels of p53 and its downstream targets p21Waf1/Cip1 and Bax in cells with Dsg3 
knockdown [8]. Collectively, these results suggest strongly that Dsg3 indeed functions as a sensor by 
modulating the p53 response to stress signals.  
 
4. Dsg3 knockdown results in DNA damage  
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Our recent study also identified the activation of the Ataxia-telangiectasia mutated (ATM) pathway 
following Dsg3 depletion in the UV setting (Figure 1) [8]. ATM is activated by DNA damage and stress 
[51] and plays a key role in regulating the DNA damage response. ATM is primarily involved in 
detecting DNA double-strand breaks (DSBs), leading ultimately to the direct or indirect (via CHK2) 
activation and stabilization of p53 [52]. DNA DSBs can be detected by the presence of either γ-H2AX 
or p53-binding protein 1 (53BP1) [53]. Our study identified significant induction of 53BP1 in Dsg3 
depleted cells, especially in those with UV exposure, and this was accompanied by upregulation of 
phosphorylated, as well as total, ATM, CHK2, and p53-S15/20, compared to the respective controls 
[8]. This data suggest that Dsg3 depletion somehow potentiates UV induced DNA damage with 
increased DNA DSBs, albeit the underlying mechanism remains obscure. It was thought that this could 
well be due to the oxidative stress caused by disruption of the intercellular junctions.     
 
5. Involvement of the Dsg3/p53 pathway in the pathogenesis of PV  
PV is a rare, severe autoimmune mucocutaneous blistering disease characterized by autoantibodies (PV-
IgG) targeting the desmosome cell adhesion complexes in keratinocytes, leading to loss of cell-cell 
adhesion (acantholysis) [3,5]. Patients with PV may suffer from malnutrition or even multiple life-
threatening complications associated with certain therapies, including bacterial and viral infection, fluid 
and electrolyte imbalances, and cardiac and renal failure [54,55]. The pathogenesis of PV remains not 
completely clear, especially for the key driver in blister formation. It was thought that multiple factors 
are involved in blistering, including steric hindrance, several intracellular signaling events (e.g. Src, 
p38MAPK, PKC. ERK, etc.), Dsg3 degradation, cell shrinkage, apoptosis and also the genetic factors 
that facilitates the production of autoantibodies against Dsg3 [5,56]. Autoantibodies binding to the 
adhesion site in the extracellular domain of Dsg3 is considered the initial and critical step in the 
pathogenesis of PV, leading to the disruption and loss of cell cohesion and ultimately blistering in the 
skin and oral mucosa [2-5]. However, the direct inhibition of Dsg3 binding is not sufficient to induce 
the complete loss of cell cohesion [57,58]. Thus the synergistic action of different pathways/events is 
considered to contribute to blistering in this disease [3,5]. Many signaling pathways are identified to 
contribute to the loss of keratinocyte cohesion, such as Src, p38MAPK, EGFR, c-Myc, and Rho 
GTPases [3,5,15-17,25,58-63]. Moreover, studies also have shown an increased incidence of apoptotic 
occurrence in acantholysis lesions of PV [41,64]. Elevated expression of pro-apoptotic proteins Bax, 
FasL, and caspases, as well as downregulation of the anti-apoptotic Bcl-2, have been reported in the 
literature [65-69]. Together, these studies have indicated that Dsg3 serves as a key receptor to transmit 
outside-in signaling that results in blister formation in PV. However, the exact role of how Dsg3 
mediates intracellular signaling is not fully understood. Moreover, studies have also suggested that the 
pathology of PV is caused by autoantibodies targeting non-Dsg3 receptors on the cell surface, thereby 
triggering intracellular signaling and leading to apoptosis and ultimately, blistering [70,71].  
 
To investigate the potential involvement of the Dsg3/p53 pathway in the pathogenesis of PV, we 
examined the biopsies from patients with PV. We showed ~50% of PV patients having a markedly 
elevated expression of p53 as well as cleaved caspase-3, indicating early apoptosis [8]. Importantly, 
these changes were found not only in cells surrounding the blisters but also in perilesional regions, 
suggesting that activation of the p53 pathway likely occurs early before the event of pemphigus 
acantholysis. Since each patient with PV may produce a unique composition of autoantibodies that 
triggers a particular pattern of signaling events [72], the observed alterations in p53 expression were 
not surprising, and this could be due to the variations of the disease status and the effect of the treatment 
received, or additionally because p53 in response to stress is transient and declines over time [73]. 
Consistent with this notion, a previous study using PV–IgG to treat keratinocytes and skin organ 
cultures showed a 50% and 40% increase of p53, respectively, compared to controls [41].  
 
The specificity of p53 induction elicited by PV-IgG targeting Dsg3 was verified by additional in vitro 
studies with PV sera that contain a pool of anti-Dsg3 antibodies (i.e. polyclonal antibodies) and also 
with the well-characterized specific pathogenic monoclonal antibody AK23 that binds the Dsg3 
adhesion site at the N-terminal [74]. The results from both experimental approaches indicated a marked 
increase of p53 as well as Bax, concomitant with Dsg3 depletion as expected based on several previous 
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studies with PV sera [14,75]. Thus, the observed findings in PV indicate a specific p53 induction 
associated with PV-IgG induced Dsg3 disturbance as this effect was demonstrated by the treatment of 
cells with anti-Dsg3 antibody AK23 in a time and dose-dependent manners [8]. Furthermore, it was 
proved that enhanced p53 is specific since the RNAi mediated p53 knockdown significantly abated the 
PV sera induced positive p53 signals. These results suggest strongly that activation of the Dsg3/p53 
pathway may contribute, at least in part, to PV pathology, with the evidence of early apoptosis that has 
been shown by others [65,68,76]. This finding may have important implications in clinical diagnosis 
and also in the development of a novel therapeutic strategy in treating this life-threatening autoimmune 
disease in the future. 
 
6. Dsg3 is involved in the regulation of YAP 
 
Our recent report also shows that Dsg3 is involved in the regulation of yes-associated protein (YAP) 
via forming a protein complex with phospho-YAP in HaCaT keratinocyte cell line [9]. Knocking down 
of Dsg3 has an impact on YAP expression at both the transcript and protein levels and causes the failure 
of YAP response to cyclic mechanical strain [77]. The same results were observed in N/TERT 
keratinocytes and showed that Dsg3 forms a protein complex with both YAP and phospho-YAP in this 
cell line (our unpublished data). Dsg3 depletion in N/TERTs also resulted in a marked reduction of both 
YAP and phospho-YAP. These results collectively indicate a permissive role for Dsg3 in the regulation 
of the YAP-Hippo pathway in keratinocytes. The Hippo pathway is another essential pathway in the 
control of cell differentiation and organ growth [78,79]. A key downstream nuclear effector and 
transcription coactivator of this pathway is YAP [77,79,80]. The activity of YAP is partially regulated 
by protein phosphorylation, including serine residue S127, leading to YAP nuclear exclusion and 
inactivation through the process of degradation or cytoplasmic accumulation via binding to 14-3-3 [79]. 
However, identification of the upstream regulators of the Hippo pathway remains limited, and 
especially, there is still a lack of the candidates for transmembrane proteins. Our findings suggest that 
Dsg3 is a potential transmembrane protein that regulates Hippo, which warrants further investigation. 
 
7. p53 and YAP antagonize each other downstream of Dsg3 
In an attempt to address the involvement of YAP in the Dsg3/p53 pathway, we performed experiments 
by knocking down of YAP or treating cells with the YAP inhibitor, and our results indicated both 
approaches caused increased p53 expression and nuclear accumulation (data not shown) (Figure 1). In 
contrast, transfection of YAP into the Dsg3 depleted cells partially rescued the phenotype of the p53 
induction. Furthermore, the antagonistic regulation between YAP and p53 was demonstrated by p53 
Luciferase assay that showed inhibition of p53 transcription activity in cells with YAP transfection, 
with an inverse effect observed in cells with YAP knockdown, as compared to the respective controls. 
Hence, it is speculated that YAP may bridge in or have an influence on the Dsg3/p53 pathway in 
keratinocytes, as shown in a working model that Dsg3 restricts p53 via YAP. This simplified model 
illustrates a relationship among these three signaling molecules in keratinocyte response to stress 
signals (Figure 1). Notably, this model places Dsg3 upstream of p53 and YAP and indicates that 
modulation of Dsg3 could have an impact on both signaling pathways, highlighting Dsg3 as an 
important component of the cellular stress response network in keratinocytes. Hence, this is another 
example among many other upstream regulators that elaborates reciprocal crosstalk between YAP and 
p53 for fine-tuning of cell proliferation and apoptosis [81,82]. 
 
The central hub in control of the balance between cellular proliferation and differentiation involves 
both fundamental pathways, p53 and Hippo-YAP signaling [78,83]. A previous study by our group 
has shown that modulation of Dsg3 has an impact on cell proliferation and Dsg3 silencing mediated 
by RNAi impaired cell proliferation and colony expansion in HaCaT keratinocyte line [12]. However, 
the underlying molecular mechanism was unclear, and it was thought that this could be due to a defect 
in cell-cell adhesion. Now, it becomes clear based on our recent findings [8,9] that this is caused by a 
reduction of YAP and suppression of YAP activity following Dsg3 depletion. p53 might also play a 
role here in Dsg3 siRNA treated HaCaT cells as p53 was reported still to be functional despite its point 
mutations in this cell line [84]. Consistent with the notion that Dsg3 regulates cell proliferation via 
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suppression of p53, overexpression of Dsg3 suppresses cell differentiation (suggesting cell de-
differentiation) and knockdown of Dsg3 results in an increase of various early keratinocyte 
differentiation markers (suggesting premature cell differentiation) in several cell lines [8,85]. As p53 
is also a well-characterized regulator in cell differentiation [86,87], it is not surprising that alteration 
of p53 can have an impact on the balance of cellular proliferation and differentiation.  
 
8. Conclusion and future perspectives 
In summary, our recent studies provide novel evidence that Dsg3 plays a role in regulating p53 
response to stress signals in keratinocytes and this pathway likely involves YAP that acts in the 
suppression of the p53 pathway. Alterations of this pathway may attribute to the pathogenesis of PV 
where Dsg3 is targeted by autoantibodies resulting in its degradation (loss of function), leading to 
heightened p53 levels and the activation of the apoptotic machinery. As a consequence, disruption of 
cell adhesion and cell shrinkage occurs that causes blistering in the Dsg3 baring tissues. The direct 
evidence of p53 in PV was lacking, and this study fills this gap, suggesting that Dsg3 signaling towards 
p53 likely reflects cellular stress response in PV. Hence this finding underscores a central role for Dsg3 
in pemphigus pathogenesis. Our finding also advances our understanding of normal physiological 
conditions. For instance, the distinct expression patterns of Dsg3 between the skin and mucous 
membrane may reflect their exposures to different environmental stresses and insults. While the oral 
mucous membrane is subject to physical and chemical insults daily, the skin is readily prone to UV 
irradiation with relative less frequency of mechanical stimulation (e.g. trunk skin). Thus this study 
sheds a light on a potential role for Dsg3 in control of tissue integrity (including the DNA) and 
homeostasis in these stress-bearing tissues and indicates the pivotal function of Dsg3 as a stress sensor 
and responder in keratinocytes beyond cell-cell adhesion. 
 
Overall, our study reveals an unprecedented role of Dsg3 in keratinocyte stress response via regulating 
the p53 and YAP pathways that paves the way for further research, especially on an emerging concept 
about the junctional proteins such as Dsg3 in control of the integrity of junctional network as well as 
the cell fate decision. An avenue to further explore is how Dsg3 is able to sense stress. An interesting 
finding from Kathleen Green’s group/laboratory has shown suppression of Dsg1, among other early 
differentiation proteins, in response to UV irradiation [88]; thus downregulation of Dsg1 in response 
to stress might potentially have influence on the Dsg3/p53 pathway, and further work in this aspect 
will help to establish this notion. Another possible avenue for future research is to characterize the 
functional association of Dsg3 and YAP by investigating if the interaction is direct or indirect via other 
scaffolding protein(s). One of our intriguing observations was that knockdown of Dsg3 resulted in the 
loss of membrane localization of phospho-YAP in keratinocytes with an effect of the nuclear retention 
in Dsg3 knockdown cells, especially in HaCaT cell line [9]. Previous studies have identified that the 
phosphorylation of YAP at S128 caused by Nemo-Like Kinase (NLK) is the key for YAP nuclear 
localization [89,90]. Thus, it was speculated that Dsg3 might negatively regulate the phosphorylation 
of YAP-S128 by suppressing NLK. It would, therefore, be interesting to analyze the phosphorylation 
at YAP-S128 and NLK and this additional information may help to elucidate whether the 
phosphorylation at S128 is regulated by Dsg3 and is required for YAP nuclear relocation in Dsg3 
depleted cells. Finally, in order to pursue the presented findings in PV towards the translational 
research with a clinical application being beneficial to patients, further studies are required to gain the 
mechanistic insight on the identified p53 signaling. Thus, insights into the activation of the apoptotic 
pathway in a spatial-temporal manner in the disease process of PV and also in the correlation between 
p53 induction and disease activity are necessary. 
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Discoid lupus erythematosus; DSB, DNA double-strand breaks; Dsg1, Desmoglein-1, Dsg, 
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Figure 1: Model for p53 activation in response to Dsg3 depletion in keratinocytes. Schematic 
illustrates our recent findings: Dsg3 depletion by RNAi or PV-IgG targeting evokes p53 upregulation, 
possibly via the induction of DNA double-strand breaks (DSBs) and/or YAP dysfunction, leading to 
p53 stabilization with an increased half-life and subsequently, the activation of p53 transcription 
function, leading to elevation of its downstream targets p21Waf1/Cip1, Bax and cleaved caspase-3. The 
functional outcome of p53 activation has been demonstrated by the myriad of studies, i.e. cell cycle 
arrest, apoptosis, and differentiation [8,12,86,91-96]. p53 silencing by RNAi abolishes the induction of 
its downstream targets in response to Dsg3 depletion. KU55933 (ATM inhibitor) was used to confirm 
the involvement of the ATM pathway and YAP inhibitor (Verteporfin, VP) and RNAi were used to 
evaluate the relationship between YAP and p53 pathway. However, how the YAP depletion can elicit 
activation of the p53 signalling pathway remains to be elucidated. P= Phosphorylation. 
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